Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma

References

• Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–1289. doi:10.1016/j.jhep.2014.01.021
   PubMed Web of Science ®Google Scholar
• Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69(4):1803–1815. doi:10.1002/hep.30289
   PubMed Web of Science ®Google Scholar
• Rodriguez H, Pennington SR. Revolutionizing precision oncology through collaborative proteogenomics and data sharing. Cell. 2018;173(3):535–539. doi:10.1016/j.cell.2018.04.008
   PubMed Web of Science ®Google Scholar
• Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111. doi:10.1038/nrclinonc.2017.157
   PubMed Web of Science ®Google Scholar
• Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391. doi:10.1172/jci80011
   PubMed Web of Science ®Google Scholar
• Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, Phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–621. doi:10.1016/s2468-1253(19)30086-x
   PubMed Web of Science ®Google Scholar
• Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353–363. doi:10.1016/j.jhep.2019.10.009
   PubMed Web of Science ®Google Scholar
• Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22(9):1265–1274. doi:10.1016/s1470-2045(21)00333-8
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584–596. doi:10.1038/nrclinonc.2015.105
   PubMed Web of Science ®Google Scholar
• Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18(5):261–279. doi:10.1038/s41571-020-00459-9
   PubMed Web of Science ®Google Scholar
• Klümper N, Saal J, Berner F, et al. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. J Immunother Cancer. 2022;10(3):e004024. doi:10.1136/jitc-2021-004024
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lu L, He Z, et al. C-reactive protein levels predict responses to PD-1 inhibitors in hepatocellular carcinoma patients. Front Immunol. 2022;13:808101. doi:10.3389/fimmu.2022.808101
   PubMed Web of Science ®Google Scholar
• Zhao QT, Yuan Z, Zhang H, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3720 patients. Int J Cancer. 2016;139(1):164–170. doi:10.1002/ijc.30060
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.024
   PubMed Web of Science ®Google Scholar
• Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360. doi:10.1186/s12916-020-01817-1
   PubMed Web of Science ®Google Scholar
• Lu LH, Zhong C, Wei W, et al. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: a multicentre cohort study. Liver Int. 2021;41(2):378–387. doi:10.1111/liv.14567
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg. 2020;272(2):342–351. doi:10.1097/sla.0000000000003239
   PubMed Web of Science ®Google Scholar
• Tan D, Fu Y, Tong W, Li F. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: a meta-analysis. Int J Surg. 2018;55:128–138. doi:10.1016/j.ijsu.2018.05.030
   PubMed Web of Science ®Google Scholar
• Ma JY, Liu Q. Clinicopathological and prognostic significance of lymphocyte to monocyte ratio in patients with gastric cancer: a meta-analysis. Int J Surg. 2018;50:67–71. doi:10.1016/j.ijsu.2018.01.002
   PubMed Web of Science ®Google Scholar
• Zhang K, Hua YQ, Wang D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med. 2019;17(1):30. doi:10.1186/s12967-019-1782-x
   PubMed Web of Science ®Google Scholar
• Nie D, Gong H, Mao X, Li Z. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: a retrospective study. Gynecol Oncol. 2019;152(2):259–264. doi:10.1016/j.ygyno.2018.11.034
   PubMed Web of Science ®Google Scholar
• Zhou J, Wei W, Hou H, et al. Prognostic value of C-reactive protein, Glasgow prognostic score, and c-reactive protein-to-albumin ratio in colorectal cancer. Front Cell Dev Biol. 2021;9:637650. doi:10.3389/fcell.2021.637650
   PubMed Web of Science ®Google Scholar
• Suzuki S, Akiyoshi T, Oba K, et al. Comprehensive comparative analysis of prognostic value of systemic inflammatory biomarkers for patients with stage II/III colon cancer. Ann Surg Oncol. 2020;27(3):844–852. doi:10.1245/s10434-019-07904-9
   PubMed Web of Science ®Google Scholar
• Kitahara H, Shoji F, Akamine T, et al. Preoperative prognostic nutritional index level is associated with tumour-infiltrating lymphocyte status in patients with surgically resected lung squamous cell carcinoma. EUR J Cardiothorac Surg. 2021;60(2):393–401. doi:10.1093/ejcts/ezab046
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y. The prognostic nutritional index is prognostic factor of gynecological cancer: a systematic review and meta-analysis. Int J Surg. 2019;67:79–86. doi:10.1016/j.ijsu.2019.05.018
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.003
   PubMed Web of Science ®Google Scholar
• Ando K, Sakamoto S, Saito S, et al. Prognostic value of high-sensitivity modified Glasgow prognostic score in castration-resistant prostate cancer patients who received docetaxel. Cancers. 2021;13(4):773. doi:10.3390/cancers13040773
   PubMed Web of Science ®Google Scholar
• Gruber ES, Jomrich G, Kaider A, Gnant M, Sahora K, Schindl M. The prognostic index independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing resection. Ann Surg Oncol. 2020;27(6):2017–2024. doi:10.1245/s10434-019-08161-6
   PubMed Web of Science ®Google Scholar
• Mei J, Sun XQ, Lin WP, et al. Comparison of the prognostic value of inflammation-based scores in patients with hepatocellular carcinoma after anti-PD-1 therapy. J Inflamm Res. 2021;14:3879–3890. doi:10.2147/jir.S325600
   PubMed Web of Science ®Google Scholar
• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–2179. doi:10.1016/s0140-6736(13)61903-0
   PubMed Web of Science ®Google Scholar
• Kasper HU, Drebber U, Stippel DL, Dienes HP, Gillessen A. Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma. World J Gastroenterol. 2009;15(40):5053–5057. doi:10.3748/wjg.15.5053
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Boor PPC, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 2017;153(4):1107–1119.e10. doi:10.1053/j.gastro.2017.06.017
   PubMed Web of Science ®Google Scholar
• Del GM, Gangestad SW. Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61–75. doi:10.1016/j.bbi.2018.02.013
   PubMed Web of Science ®Google Scholar
• Sieghart W, Pinter M, Hucke F, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology. 2013;57(6):2224–2234. doi:10.1002/hep.26057
   PubMed Web of Science ®Google Scholar
• Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity. Autoimmun Rev. 2019;18(3):306–311. doi:10.1016/j.autrev.2018.10.005
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/s1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019;39(11):2008–2023. doi:10.1111/liv.14220
   PubMed Web of Science ®Google Scholar
• Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–363. doi:10.1016/j.jhep.2021.09.035
   PubMed Web of Science ®Google Scholar
• Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005;92(4):651–654. doi:10.1038/sj.bjc.6602419
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ichikawa J, Giuroiu I, et al. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. J Immunother Cancer. 2020;8(1):e000234. doi:10.1136/jitc-2019-000234
   PubMed Web of Science ®Google Scholar